The Effect of a Brief Intervention on Behavıoral Change, Anthropometric and Metabolic Variables

July 31, 2025 updated by: Yasemin Guven, Mersin University

The Effect of Brief Interventıon on Behavıoral Change, Anthropometrıc and Metabolıc Varıables In Overweıght Women wıth Low Health Lıteracy

This study will evaluate the effect of a brief intervention on anthropometric and metabolic changes in overweight women with low health literacy. The total number of samples was determined as 88. It was decided to recruit a total of 124 people, 62 people in each group, with a 40% loss in the groups. Brief intervention interviews will be conducted with the intervention group. Brief intervention interviews will take an average of 20-30 minutes and four times. The control group will not be intervened except for the first and last evaluations.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study will evaluate the effect of a brief intervention on anthropometric and metabolic changes in overweight women with low health literacy. The total number of samples was determined as 88, 44 in each of the intervention and control groups. It was decided to recruit a total of 124 people, 62 people in each group, with a 40% loss in the groups. Randomization will be performed after obtaining consent from the participants who meet the eligibility and exclusion criteria. The sampled individuals will be assigned to the Intervention and Control groups according to the block randomization method. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. At the end of brief interventions applied to overweight women with low health literacy for 20-30 minutes, a total of four times; weight change, waist circumference change, blood pressure change, blood glucose change, blood lipid change, diet, and exercise behaviors will be evaluated. The control group will not be intervened except for the first and last evaluations.

Study Type

Interventional

Enrollment (Actual)

124

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Mersin, Turkey
        • Turkey, Mersin University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Having heart disease, stroke, and chronic kidney failure diagnosed by a physician,
  • Having diabetes that requires the use of insulin,
  • Having hypothyroidism that prevents weight loss,
  • Participating in a weight management program in the last 3 months,
  • Being diagnosed with a disease that causes deterioration in cognitive processes such as Alzheimer's and dementia,
  • Having a diagnosed physical or neurological problem that prevents him from doing physical activity,
  • People who plan to become pregnant or become pregnant during the trial period (8 months after enrollment in the trial)

Exclusion Criteria:

  • Between 12.09.2023 and 24.06.2024 two Primary healthcare organization applied,
  • Volunteered to participate in the research,
  • Women between the ages of 30-65,
  • The level of health literacy is limited-restricted,
  • 25≥ BMI < 30,
  • Those who can read and understand Turkish will be included in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Brief intervention
Intervention Group: Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
No Intervention: Control
The control group will not be intervened except for the first and last face-to-face evaluation. At the end of the research, training materials for weight loss will be given.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of weight change
Time Frame: Change from before implementation three and six months of practice.
The weight will be evaluated by measuring the weight.
Change from before implementation three and six months of practice.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The exercise habits will be evaluated using the Exercise Behavior Change Model Scales.
Time Frame: Change from before implementation and six months of practice.
The highest score that can be obtained from the scale is 140, and the lowest score is 28. The higher the scale score indicates that the individual's chance of being successful in change increases.
Change from before implementation and six months of practice.
The eating habits will be evaluated using the Nutrition Processes of Change Scale.
Time Frame: Change from before implementation and six months of practice.
The highest score that can be obtained from the scale is 240, and the lowest score is 48. Higher scores from the scale indicate more positive values for change.
Change from before implementation and six months of practice.
The Mediterranean diet will be evaluated using the Mediterranean Diet Adherence Screener (MEDAS).
Time Frame: Change from before implementation and six months of practice.
A total score of 7 and 8 on the scale indicates an acceptable degree of adherence to the Mediterranean diet, and a score of 9 and above indicates strict adherence to the Mediterranean diet.
Change from before implementation and six months of practice.
Waist circumference measurement and evaluation
Time Frame: Change from before implementation, three and six months of practice.
Waist circumference will be measured by the researcher with a tape measure from the thinnest part of the waist at the level of the navel, passing through the anterior superior of the spina iliaca. Waist circumference <80 will be considered "low risk", >80-88 will be considered "high risk" and >88 will be considered "very high risk."
Change from before implementation, three and six months of practice.
Measurement and evaluation of blood pressure (BP)
Time Frame: Change from before implementation, three and six months of practice.
By the Hypertension Diagnosis and Treatment Guidelines, measures will be made on both arms, and the average will be recorded. BP below 120/80 mmHg is normal, mean systolic BP of 120-139 mmHg and/or mean diastolic BP of 80-89 mmHg increased, and mean systolic BP ≥140 mmHg and/or mean diastolic BP ≥90 mmHg will be considered hypertension.
Change from before implementation, three and six months of practice.
Evaluation of fasting plasma glucose level
Time Frame: Change from before implementation and six months of practice.
"Fasting plasma glucose" ≥ 126 mg/dl or "suspected diabetes mellitus" if values of "200 mg/dl" and above in a random measurement area will be evaluated as.
Change from before implementation and six months of practice.
Evaluation of glycosylated hemoglobin A1c (HbA1c) level
Time Frame: Change from before implementation and six months of practice.
A1c 5.7-6.4% (39-47 mmol/mol) will be considered a "high-risk group." A1c ≥6.5% (≥48 mmol/mol) will be considered as "diabetes mellitus."
Change from before implementation and six months of practice.
Evaluation of blood lipid changes (Total cholesterol, HDL, LDL cholesterol, and triglyceride level)
Time Frame: Change from before implementation and six months of practice.

Total cholesterol <200 mg/dL is considered "optimal," 200-239 mg/dL is "borderline high" and >240 mg/dL is "high". will be evaluated.

HDL cholesterol ≥60 mg/dL will be considered "optimal", 50-59 mg/dL will be considered "borderline high" and <50 mg/dL will be considered "high."

LDL cholesterol <100 mg/dL will be considered "optimal", 100-129 mg/dL will be considered "normal," 130-159 mg/dL will be considered "borderline high" and ≥160-189 mg/dL will be considered ''high,'' ≥190 mg/dL will be considered "very high."

A triglyceride of <150 mg/dL will be considered "normal,"150-199 mg/dL will be considered "borderline high," 200-500 mg/dL will be considered "high" and ≥500 mg/dL will be considered "very high."

Change from before implementation and six months of practice.
Body mass index (BMI) evaluation
Time Frame: Change from before implementation, three and six months of practice.
BMI <18.5-24.9 kg/m2 will be defined as "normal", BMI between 25-29.9 kg/m2 will be defined as "overweight", and BMI≥ 30 kg/m2 will be defined as "obese".
Change from before implementation, three and six months of practice.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yasemin Güven, Master, Mersin University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 16, 2023

Primary Completion (Actual)

April 24, 2024

Study Completion (Actual)

October 9, 2024

Study Registration Dates

First Submitted

July 2, 2023

First Submitted That Met QC Criteria

August 4, 2023

First Posted (Actual)

August 7, 2023

Study Record Updates

Last Update Posted (Actual)

August 5, 2025

Last Update Submitted That Met QC Criteria

July 31, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • MeU-YGUVEN-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brief Intervention

Clinical Trials on Brief intervention

Subscribe